We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Viral Shedding Studies Focus of U.S. FDA Final Guidance
Viral Shedding Studies Focus of U.S. FDA Final Guidance
Biologics makers developing drugs based on bacteria and viruses should conduct preclinical and clinical studies to determine if infection could be unintentionally transmitted from treated patients to other individuals, the U.S. Food and Drug Administration says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor